Articles: ninos.
-
Health Professions Scholarship Program (HPSP) medical students typically enter the military with minimal military experience, commissioning specifically for the scholarship. During medical school, the only required training is a 5- to 6-week officer training course, which is neither specific to medicine nor guaranteed to be at the beginning of school, since it can be taken at any time. This lack of prior experience can lead to decreased confidence and understanding of the HPSP, specifically the medical school timeline leading up to the military match process and overall military. Our study investigated the effect of implementing a new military-specific orientation module on improving students' confidence and specific knowledge about the HPSP and military training. ⋯ Overall, the students felt more confident regarding the HPSP and showed improved knowledge after the orientation program. We found higher baseline knowledge regarding active duty tours, which their coordinators communicate well with HPSP students. Similar orientation programs could effectively improve the onboarding process of incoming HPSP students and those interested in applying for HPSP across multiple medical schools. Such programs can improve long-term student satisfaction and the duration of service following the minimum service commitments. Future research with a larger sample size and prospective design is needed to understand the long-term effects of this increased confidence on overall program satisfaction and military career.
-
Randomized Controlled Trial Multicenter Study
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in patients with unresectable, non-metastatic hepatocellular carcinoma. ⋯ Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc, Rahway, NJ, USA, and Eisai, Nutley, NJ, USA.